Austrian Court Upholds Novogen Patent for Red Clover Isoflavones
June 20 2006 - 9:00AM
PR Newswire (US)
STAMFORD, Conn. and SYDNEY, Australia, June 20
/PRNewswire-FirstCall/ -- The Vienna Commercial Court has found
that Novogen's (NASDAQ:NVGN)(ASX: Novogen) isoflavone invention and
patent is novel and inventive. The Court found APOtrend's menopause
product Vitalady infringed Novogen's patent and the provisional
injunction against Vitalady has been upheld. As a preliminary
question the Court assumed the validity of Novogen's patent.
APOtrend is now required to retract all infringing Vitalady
products from retail, wholesale and any other channels of sale.
Novogen's representative in Austria, Renate Moser, said that the
Court decision was also a confirmation of the inventiveness of
Novogen's patent. "The Vienna Commercial Court findings are a
reflection of similar patent success Novogen has experienced in
Canada and USA. Novogen will continue to protect and enforce its
intellectual property rights around the world for the benefit of
users of nutritional supplements", Moser said. The Company has
provided a guarantee to the value of 250.000 Euros with the
Austrian Court to confirm its commitment to the ongoing enforcement
process. Novogen believes the protection of Intellectual Property
is a fundamental step in the development of high quality
nutritional supplements with standardized active ingredients that
are clinically supported for the benefit of consumers, health care
professionals and retailers. About Novogen Novogen is an Australian
based biotechnology company in the business of research and
development of drugs derived from its phenolic technology platform.
The Company manages its research and development programs utilizing
the expertise and clinical research capabilities of universities
and hospitals in Australia, USA and Europe. Novogen's drug program
is researching and developing compounds for the treatment of
cancer, cardiovascular disease and osteoarthritis. To date Novogen
has had 51 patents granted and a further 240 patents are pending.
Novogen's consumer business has conducted the largest and most
comprehensive isoflavone clinical testing program in the world.
Novogen's consumer brands Promensil, and Trinovin are clinically
supported, natural products for women and men's health. Patents
supporting Novogen's consumer brands have been granted in USA,
Europe, Canada and Australia. Further information on the Novogen
Group can be found at http://www.novogen.com/. Under U.S. law, a
new drug cannot be marketed until it has been investigated in
clinical trials and approved by the FDA as being safe and effective
for the intended use. Statements included in this press release
that are not historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that
our actual results could differ materially from those contained in
the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Novogen Limited
CONTACT: David Sheon, +1-202-518-6321, for Novogen Limited; or
Chris Naughton, Managing Director of Novogen Limited, +02 9878 0088
Web site: http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024